Concerns growing over public health

The end of the free trade agreement (FTA) will be a big blow to Korean pharmaceutical firms that rely much of the revenue on the sales of generic drugs, and also threaten the government's ability to control the prices.

Under the deal, U.S. drug makers will be able to secure longer exclusive sales periods for their products in Korea. They will also have more control when determining the price...